Find information on thousands of medical conditions and prescription drugs.

Cardura

Doxazosin mesylate, a quinazoline compound sold by Pfizer under the brand name Cardura, is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.

Its empirical formula is C23H25N5O5•CH4O3S, and it has a molecular weight of 547.6.

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Andrx pulls plug on brands
From Drug Store News, 2/14/05 by Michael Johnsen

FORT LAUDERDALE, Fla. -- Andrx has decided to exit the branded business altogether after waiting some 14 months for the approval of Pfizer's Cardura XL.

Andrx originally acquired the U.S. distribution rights to the extended-release alpha-blocker in November 2003 for an agreed upon $35 million. At the time, the approval for the benign prostatic hyperplasia treatment was expected to come in the summer of 2004, and projected sales were expected to reach in excess of $100 million annually, as reported by David Buck, an analyst with the Buckingham Research Group.

With Cardura XL yet to be approved and Andrx's current brand portfolio operating on a $31 million deficit for the nine months ended Sept. 30, company directors opted to focus on core competencies. "Our board and management have been evaluating our overall strategy and have concluded that Andrx should focus on ... controlled-release pharmaceuticals and distribution, as well as initiatives ... that will cause our controlled-release technologies to be employed in the development of new brand products for third parties," said Andrx Chief Executive Officer Thomas Rice.

In contrast with its branded efforts, Andrx recorded a profit of $104.8 million on revenues of $303.3 million from the sales of generic products and a profit of $37.4 million on revenues of $495 million from distribution agreements.

Andrx exercised its right to terminate the Cardura XL agreement with Pfizer when the drug was not approved by Dec. 31. Andrx is expected to receive a refund of the $10 million the company paid in connection with the deal.

The challenge for Andrx now may be in persuading another company to assume its brand portfolio. "We are unsure about Andrx's ability to find a buyer willing to pay much of a multiple to sales," remarked A.G. Edwards analyst Al Rauch. Branded products Altoprev [lovastatin extended release] and Fortamet [metformin HC1 extended release] have only three years of marketing exclusivity, and generics companies are challenging patents that extend beyond this time."

In addition, the future for the supplier's two cough-cold formulations, Entex PSE and Entex LA, is "uncertain," according to the company, amid speculation that Entex PSE may have to be pulled from the market following Adams Respiratory Therapeutics' Food and Drug Administration approval for an over-the-counter version of pseudoephedrine and guaifenesin, Mucinex D, in June 2004.

Andrx optimistically anticipates the sale of its branded business within roughly six months and has engaged Banc of America Securities to broker the deal.

COPYRIGHT 2005 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2005 Gale Group

Return to Cardura
Home Contact Resources Exchange Links ebay